{"id":"standard-chemo-or-endocrine-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Hot flashes (endocrine therapy)"},{"rate":null,"effect":"Vaginal dryness (endocrine therapy)"},{"rate":null,"effect":"Alopecia (chemotherapy)"}]},"_chembl":{"chemblId":"CHEMBL261657","moleculeType":"Small molecule","molecularWeight":"405.37"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Chemotherapy agents (such as taxanes, anthracyclines, or alkylating agents) induce DNA damage and cell cycle arrest, leading to apoptosis in cancer cells. Endocrine therapy (such as tamoxifen, aromatase inhibitors, or fulvestrant) blocks estrogen or progesterone signaling pathways critical for growth of hormone receptor-positive cancers. These are broad therapeutic categories rather than single drugs.","oneSentence":"Standard chemotherapy and endocrine therapy work through distinct mechanisms: chemotherapy damages DNA to kill rapidly dividing cancer cells, while endocrine therapy blocks hormone signaling in hormone-sensitive cancers.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:36:10.255Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer (adjuvant or metastatic setting)"},{"name":"Various solid tumors (chemotherapy component)"}]},"trialDetails":[{"nctId":"NCT07391774","phase":"PHASE3","title":"Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-07","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8","enrollment":1978},{"nctId":"NCT00310180","phase":"PHASE3","title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-04-07","conditions":"Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7","enrollment":10273},{"nctId":"NCT01272037","phase":"PHASE3","title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-28","conditions":"Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma","enrollment":5018},{"nctId":"NCT07106632","phase":"PHASE3","title":"Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-04-01","conditions":"Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer","enrollment":3380},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT07112053","phase":"PHASE2","title":"A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-11-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma","enrollment":40},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT07421141","phase":"PHASE2","title":"De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Radiological Centre of the Ministry of Health of Russia","startDate":"2023-09-01","conditions":"Breast Cancer, HER2-positive Breast Cancer, Early Breast Cancer","enrollment":186},{"nctId":"NCT03808337","phase":"PHASE2","title":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-01-16","conditions":"Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer","enrollment":145},{"nctId":"NCT06127979","phase":"NA","title":"A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-06","conditions":"Breast Cancer","enrollment":42},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT07407920","phase":"PHASE2","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma","enrollment":120},{"nctId":"NCT07344779","phase":"","title":"A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-02-17","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1600},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT03556904","phase":"PHASE2","title":"FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2018-12-10","conditions":"Prostate Cancer","enrollment":14},{"nctId":"NCT04134260","phase":"PHASE3","title":"Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2020-04-16","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8","enrollment":586},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT05717166","phase":"PHASE3","title":"A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.","status":"RECRUITING","sponsor":"David Palma","startDate":"2023-10-06","conditions":"Metastatic Tumor","enrollment":180},{"nctId":"NCT07305246","phase":"PHASE2","title":"Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2025-12","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT07003763","phase":"NA","title":"Electroacupuncture on Treating Cancer-related Depression","status":"RECRUITING","sponsor":"Shanghai Municipal Hospital of Traditional Chinese Medicine","startDate":"2025-07-01","conditions":"Depression, Cancer","enrollment":86},{"nctId":"NCT00929214","phase":"PHASE2","title":"Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06-24","conditions":"Breast Cancer","enrollment":35},{"nctId":"NCT01723774","phase":"PHASE2","title":"PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2013-04-10","conditions":"Breast Neoplasms","enrollment":84},{"nctId":"NCT07269691","phase":"PHASE3","title":"RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Pengfei Qiu","startDate":"2025-12-01","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer","enrollment":194},{"nctId":"NCT02530177","phase":"","title":"Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-08-19","conditions":"Non-Metastatic Breast Cancer","enrollment":546},{"nctId":"NCT05914116","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"DualityBio Inc.","startDate":"2023-08-17","conditions":"Advanced Solid Tumors","enrollment":862},{"nctId":"NCT07213206","phase":"PHASE3","title":"CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-07","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT07050563","phase":"NA","title":"Clinical Evaluation of the Tiaoshen Anti-Cancer Regimen in Treating Psycho-Neurological Symptom Cluster in Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Municipal Hospital of Traditional Chinese Medicine","startDate":"2025-10-06","conditions":"Cancer, Cancer Symptom Clusters","enrollment":316},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT07106112","phase":"NA","title":"Carbon Suspension vs. Metallic Marker for Axillary Lymph Node Marking in Breast Cancer After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Saint Petersburg State University, Russia","startDate":"2025-05-15","conditions":"Breast Cancer","enrollment":110},{"nctId":"NCT07013422","phase":"NA","title":"The Effectiveness of Psychoeducational Intervention in Reducing Anxiety, Depression, and Symptom Burden Among Omani Women Diagnosed With Breast Cancer","status":"COMPLETED","sponsor":"Sultan Qaboos Comprehensive Cancer Center","startDate":"2022-12-05","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":58},{"nctId":"NCT02476786","phase":"PHASE2","title":"Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-17","conditions":"Breast Cancer, Cancer of Breast, Breast Neoplasms","enrollment":50},{"nctId":"NCT05837455","phase":"PHASE2","title":"NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-30","conditions":"Breast Cancer, Cancer of the Breast","enrollment":81},{"nctId":"NCT03725059","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-27","conditions":"Breast Cancer","enrollment":1240},{"nctId":"NCT04115007","phase":"PHASE3","title":"Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-23","conditions":"Oligometastatic Hormone Sensitive Prostate Cancer","enrollment":550},{"nctId":"NCT06864533","phase":"NA","title":"Adjuvant Chemotherapy for High Malignant Prostate Cancer","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2019-09-01","conditions":"Prostate Cancer, Radiation Therapy, Chemotherapy","enrollment":315},{"nctId":"NCT02204098","phase":"PHASE1","title":"Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2015-01-07","conditions":"Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast","enrollment":27},{"nctId":"NCT03314688","phase":"NA","title":"Lifestyle, Exercise, and Nutrition Study Early After Diagnosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2018-01-02","conditions":"Breast Neoplasms","enrollment":173},{"nctId":"NCT03227328","phase":"PHASE2","title":"CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-08-02","conditions":"Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Negative Breast Cancer","enrollment":52},{"nctId":"NCT01619111","phase":"PHASE3","title":"DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs","status":"COMPLETED","sponsor":"Prof. Wolfgang Janni","startDate":"2012-02","conditions":"HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells","enrollment":105},{"nctId":"NCT03272477","phase":"PHASE2","title":"Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients","status":"COMPLETED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-10-05","conditions":"Breast Neoplasms","enrollment":257},{"nctId":"NCT04383275","phase":"PHASE2","title":"Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2021-08-23","conditions":"Breast Cancer","enrollment":356},{"nctId":"NCT03609047","phase":"PHASE2","title":"Adjuvant Palbociclib in Elderly Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2019-06-14","conditions":"Breast Cancer Stage II, Breast Cancer Stage III","enrollment":366},{"nctId":"NCT00499083","phase":"PHASE2","title":"Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-05-01","conditions":"Breast Cancer","enrollment":17},{"nctId":"NCT05569811","phase":"PHASE2","title":"NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-11-25","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT04930055","phase":"","title":"Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)","status":"TERMINATED","sponsor":"Indiana University","startDate":"2021-06-30","conditions":"Cancer","enrollment":2206},{"nctId":"NCT03636776","phase":"NA","title":"Quality of Life and Psychological Vulnerability in Patients With RH+ Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2016-12-29","conditions":"Metastatic Breast Cancer, Positive Hormonal Receptors","enrollment":60},{"nctId":"NCT05345860","phase":"NA","title":"Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-03-24","conditions":"Early-stage Breast Cancer","enrollment":300},{"nctId":"NCT04646564","phase":"PHASE3","title":"Radiotherapy for Extracranial Oligometastatic Breast Cancer","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-04-06","conditions":"Breast Cancer Metastatic","enrollment":170},{"nctId":"NCT02132949","phase":"PHASE2","title":"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07-14","conditions":"Breast Cancer","enrollment":401},{"nctId":"NCT04922008","phase":"PHASE2","title":"Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":356},{"nctId":"NCT03514654","phase":"NA","title":"MIAMI Safe Surgery for Multiple Breast Cancers","status":"COMPLETED","sponsor":"University College, London","startDate":"2017-11-01","conditions":"Breast Cancer, Unilateral","enrollment":4},{"nctId":"NCT00296010","phase":"PHASE3","title":"Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2005-08","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT03997539","phase":"PHASE2","title":"A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-08-15","conditions":"Metastatic Breast Cancer","enrollment":256},{"nctId":"NCT01796444","phase":"PHASE3","title":"Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node","status":"WITHDRAWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2013-01","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT03294122","phase":"","title":"Predictors of Normal Tissue Response From the Microenvironment in Radiotherapy for Prostate and Head-and-neck Cancer","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2017-02-02","conditions":"Prostate Cancer, Head and Neck Cancer","enrollment":400},{"nctId":"NCT03213925","phase":"PHASE2","title":"Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2017-06-01","conditions":"Breast Cancer, Radiation Therapy","enrollment":1},{"nctId":"NCT01419197","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Breast Cancer","enrollment":602},{"nctId":"NCT01368263","phase":"PHASE2","title":"Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2011-09","conditions":"Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Stage II Breast Cancer","enrollment":8},{"nctId":"NCT00452556","phase":"PHASE2","title":"The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study","status":"UNKNOWN","sponsor":"Nova Scotia Cancer Centre","startDate":"2007-05","conditions":"Prostatic Neoplasms","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16364,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"standard chemo- or endocrine therapy","genericName":"standard chemo- or endocrine therapy","companyName":"Prof. Wolfgang Janni","companyId":"prof-wolfgang-janni","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Standard chemotherapy and endocrine therapy work through distinct mechanisms: chemotherapy damages DNA to kill rapidly dividing cancer cells, while endocrine therapy blocks hormone signaling in hormone-sensitive cancers. Used for Hormone receptor-positive breast cancer (adjuvant or metastatic setting), Various solid tumors (chemotherapy component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}